author-photo

Yu-Waye Chu

Genentech

46

Papers

2264

Citations

Citation Trend

Filter By

Papers (32) Sort By

Journal Conference Others

Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma

2021 Immunology
Show All
- Source
- Cite
- Save
Citations (1)
Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

2020 Blood
Show All
- Source
- Cite
- Save
Citations (7)
Development of a Novel MICA/B-Specific CAR As a Pan-Tumor Targeting Strategy for Off-the-Shelf, Cell-Based Cancer Immunotherapy

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

2020 Blood
Show All
- Source
- Cite
- Save
Citations (4)
A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling.

2020
Show All
- Source
- Cite
- Save
Citations (11)
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

2019 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (89)
Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

2018 Blood
Show All
- Source
- Cite
- Save
Citations (34)